ATE516802T1 - Verfahren zur modulierung der phototoxizität - Google Patents

Verfahren zur modulierung der phototoxizität

Info

Publication number
ATE516802T1
ATE516802T1 AT03728425T AT03728425T ATE516802T1 AT E516802 T1 ATE516802 T1 AT E516802T1 AT 03728425 T AT03728425 T AT 03728425T AT 03728425 T AT03728425 T AT 03728425T AT E516802 T1 ATE516802 T1 AT E516802T1
Authority
AT
Austria
Prior art keywords
modulating
phototoxicity
enhance
methods
ultraviolet light
Prior art date
Application number
AT03728425T
Other languages
English (en)
Inventor
G T Wondrak
Michael J Roberts
Moonsun Kim
M K Jacobson
E L Jacobson
Original Assignee
Univ Arizona State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona State filed Critical Univ Arizona State
Application granted granted Critical
Publication of ATE516802T1 publication Critical patent/ATE516802T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/57—Compounds covalently linked to a(n inert) carrier molecule, e.g. conjugates, pro-fragrances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Birds (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Radiation-Therapy Devices (AREA)
  • Photovoltaic Devices (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03728425T 2002-04-19 2003-04-17 Verfahren zur modulierung der phototoxizität ATE516802T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37403302P 2002-04-19 2002-04-19
PCT/US2003/011842 WO2003088909A2 (en) 2002-04-19 2003-04-17 Methods for modulating phototoxicity

Publications (1)

Publication Number Publication Date
ATE516802T1 true ATE516802T1 (de) 2011-08-15

Family

ID=29251125

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03728425T ATE516802T1 (de) 2002-04-19 2003-04-17 Verfahren zur modulierung der phototoxizität

Country Status (17)

Country Link
US (3) US6992071B2 (de)
EP (1) EP1496891B1 (de)
JP (2) JP4527405B2 (de)
CN (1) CN1298321C (de)
AT (1) ATE516802T1 (de)
AU (1) AU2003234119B2 (de)
CA (2) CA2482320C (de)
CY (1) CY1112194T1 (de)
DK (1) DK1496891T3 (de)
ES (1) ES2367258T3 (de)
HK (1) HK1077761B (de)
IL (2) IL164560A0 (de)
MX (1) MXPA04010228A (de)
NZ (1) NZ535982A (de)
PT (1) PT1496891E (de)
RU (1) RU2301800C2 (de)
WO (1) WO2003088909A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04010228A (es) * 2002-04-19 2005-06-08 Univ Arizona Metodos para modular la fotoxicidad.
CA2716797A1 (en) * 2008-03-10 2009-09-17 Basf Se Encapsulated phase change materials in seed coatings
AU2010231598A1 (en) * 2009-03-30 2011-11-10 Shiseido Company, Ltd. Composition for alleviating ultraviolet radiation-induced damage

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310461A (en) * 1980-06-23 1982-01-12 E. R. Squibb & Sons, Inc. Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids
US4902684A (en) * 1988-06-20 1990-02-20 E. R. Squibb & Sons, Inc. Benzazepine and benzothiazepine derivatives
US6309440B1 (en) * 1998-08-25 2001-10-30 Thomas T. Yamashita Method and composition for promoting and controlling growth of plants
US5208249A (en) * 1992-08-20 1993-05-04 Clintec Nutrition Co. Method for stimulating intracellular synthesis of glutathione using esters of L-2-oxothiazolidine-4-carboxylate
JPH0797322A (ja) * 1993-09-29 1995-04-11 Shiseido Co Ltd 一重項酸素消去剤
US5681554A (en) * 1995-06-28 1997-10-28 Cosmair, Inc. Composition for treating hair and method for using the same
US6013250A (en) * 1995-06-28 2000-01-11 L'oreal S. A. Composition for treating hair against chemical and photo damage
JP2961074B2 (ja) * 1995-09-06 1999-10-12 明治製菓株式会社 光化学療法用の新生血管閉塞剤
JPH09249567A (ja) * 1996-01-12 1997-09-22 Otsuka Pharmaceut Co Ltd 医薬組成物
ATE253885T1 (de) * 1996-05-07 2003-11-15 Eric F Bernstein Topische verwendung von tempol zur vorbeugung der lichtalterung
US20010056085A1 (en) * 1996-07-09 2001-12-27 Avner Ramu Methods of using vesicant drug formulations
CA2266412A1 (en) * 1996-09-18 1998-03-26 William J. Sarill Compositions containing cobalamin and amino acids
WO1998043976A1 (fr) * 1997-03-31 1998-10-08 Wakamoto Pharmaceutical Co., Ltd. Derives de biphenyle et compositions medicinales
US6103487A (en) * 1997-08-27 2000-08-15 Merck & Co., Inc. Method of treating cancer
FR2775595B1 (fr) * 1998-03-09 2000-05-05 Seppic Sa Composition synergique comprenant un compose a structure lipoaminoacide et un extrait de menuphar
JPH11255715A (ja) * 1998-03-13 1999-09-21 Kao Corp Ｎ，ｎ−ジ置換アニリン誘導体
US20020006418A1 (en) * 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
FR2792650B1 (fr) * 1999-04-20 2003-02-28 Oreal Equivalent de peau agee, son procede de preparation et son utilisation
KR20020023941A (ko) * 1999-04-30 2002-03-29 오베르더 왈터 산화방지성 비타민 ｂ6 유사체
WO2000066119A1 (en) * 1999-05-05 2000-11-09 Merck & Co., Inc. Novel prolines as antimicrobial agents
US20020006394A1 (en) * 2000-02-11 2002-01-17 Redmond Robert W. Photochemical tissue bonding
US6464992B2 (en) * 2000-04-14 2002-10-15 University Of Kentucky Research Foundation Topical micronutrient delivery system and uses thereof
US20030185864A1 (en) * 2000-07-19 2003-10-02 Asako Kobayashi Preventives or remedies for atopic dermatitis
JP2002128651A (ja) * 2000-10-25 2002-05-09 Kose Corp 光老化抑制剤およびそれを含有することを特徴とする皮膚外用剤
WO2002062251A2 (en) * 2001-02-05 2002-08-15 Buchanan L Stephen Multi-tapered dental files
MXPA04010228A (es) * 2002-04-19 2005-06-08 Univ Arizona Metodos para modular la fotoxicidad.
DE102005000868A1 (de) * 2004-10-15 2006-04-20 Henkel Kgaa Zusammensetzungen mit Inhibitoren der Prostaglandin- und/oder Leukotrien-Synthese in Kombination mit Stimulatoren der Freisetzung kutaner Neuromediatoren

Also Published As

Publication number Publication date
EP1496891B1 (de) 2011-07-20
US20060009416A1 (en) 2006-01-12
CA2482320C (en) 2010-02-09
JP2010163461A (ja) 2010-07-29
WO2003088909A3 (en) 2004-02-12
JP4527405B2 (ja) 2010-08-18
ES2367258T3 (es) 2011-10-31
CA2668311A1 (en) 2003-10-30
IL203968A0 (en) 2011-07-31
AU2003234119A1 (en) 2003-11-03
EP1496891A4 (de) 2009-10-21
RU2301800C2 (ru) 2007-06-27
HK1077761B (zh) 2007-05-25
EP1496891A2 (de) 2005-01-19
US7226937B2 (en) 2007-06-05
HK1077761A1 (en) 2006-02-24
NZ535982A (en) 2006-10-27
US6992071B2 (en) 2006-01-31
CA2482320A1 (en) 2003-10-30
MXPA04010228A (es) 2005-06-08
CN1298321C (zh) 2007-02-07
US20050042188A1 (en) 2005-02-24
AU2003234119B2 (en) 2007-02-08
CA2668311C (en) 2011-08-02
WO2003088909A2 (en) 2003-10-30
DK1496891T3 (da) 2011-10-24
IL203968A (en) 2013-02-28
RU2004133322A (ru) 2005-08-10
PT1496891E (pt) 2011-09-02
CN1646121A (zh) 2005-07-27
JP5244150B2 (ja) 2013-07-24
IL164560A0 (de) 2005-12-18
US20030223941A1 (en) 2003-12-04
CY1112194T1 (el) 2015-12-09
JP2005534625A (ja) 2005-11-17

Similar Documents

Publication Publication Date Title
ATE435209T1 (de) Verfahren zur herstellung von montelukast-natrium
ATE425136T1 (de) Verfahren zur herstellung substituierter 3-aryl- butyl-aminverbindungen
ATE469957T1 (de) Verfahren zur herstellung von ölzusammensetzungen
DE602006021223D1 (de) Verfahren zur identifizierung von trpv2-modulatoren
DE602006011457D1 (de) Verfahren zur herstellung von 3alpha(beta)-7alpha(beta)-dihydroxy-6alpha(beta)-alkyl-5beta-cholansäure
DE112004001806D2 (de) Verfahren zur Selbstjustierenden Verkleinerung von Strukturen
DE602006010400D1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
DE602004020895D1 (de) Verfahren zur herstellung von kohlenstoffnanospulen
ATE455778T1 (de) Verfahren zur herstellung form i von (s)-(+)- clopidogrelbisulfat
ATE405374T1 (de) Verfahren zur herstellung von brillengläsern
ATE453619T1 (de) Verfahren zur herstellung von hydroperoxiden
DE60325194D1 (de) Methoden zur verwendung von lamellaren körpern für therapeutische zwecke
ATE516802T1 (de) Verfahren zur modulierung der phototoxizität
DE602004014264D1 (de) Verfahren zur herstellung von olanzapin
ATA14432002A (de) Verbessertes verfahren zur singlet sauerstoff oxidation von organischen substraten
ATA16992003A (de) Verfahren zur qualitätssicherung von langholz
ATE397085T1 (de) Verfahren zur reproduzierung von pleuromutilinen
ATE471941T1 (de) Verfahren zur herstellung von thiazolopyrimidinen
ATE356128T1 (de) Verfahren zur herstellung von tubulininhibitoren
ATE402948T1 (de) Verfahren zur aufreinigung eines nichtimmunoglobulinproteins, das eine immunoglobulinähnliche (ig-like) domäne enthält
ATE425163T1 (de) Verfahren zur herstellung von chinuclidiniumcarbamatderivaten
ATE382035T1 (de) Verfahren zur herstellung von n-substituierten phthalimiden
ATE477244T1 (de) Verfahren zur herstellung von bengamide-derivaten
ATE468323T1 (de) Verfahren zur hertellung von 2-cyan-3-hydroxy-n- (phenyl)but-2-enamiden
DE502004000843D1 (de) Verfahren zur anodischen alkoxylierung von organischen verbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1496891

Country of ref document: EP